Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2008-12-24
2011-11-15
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C514S002600, C530S350000
Reexamination Certificate
active
08057802
ABSTRACT:
The present invention relates to the ability of SAP to suppress fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress fibrocytes. Methods and compositions for suppressing fibrocytes using these proteins are provided. These methods are useful in a variety of applications including treatment and prevention of fibrosing diseases such as scleroderma, pulmonary fibrosis and asthma. Finally, the invention includes assays for detecting the ability of various agents to modulate differentiation into fibrocytes. Such assays may also be used to diagnose scleroderma, pulmonary fibrosis, or other fibrosing diseases.
REFERENCES:
patent: 4233969 (1980-11-01), Lock et al.
patent: 4556056 (1985-12-01), Fischer et al.
patent: 4782014 (1988-11-01), Serban et al.
patent: 5092876 (1992-03-01), Dhawan et al.
patent: 5654186 (1997-08-01), Cerami et al.
patent: 5698589 (1997-12-01), Allen
patent: 5804446 (1998-09-01), Cerami et al.
patent: 5846796 (1998-12-01), Cerami et al.
patent: 6037458 (2000-03-01), Hirai et al.
patent: 6054121 (2000-04-01), Cerami et al.
patent: 6126918 (2000-10-01), Pepys et al.
patent: 6174526 (2001-01-01), Cerami et al.
patent: 6365570 (2002-04-01), Van Kessel et al.
patent: 6406698 (2002-06-01), Svehag et al.
patent: 6537811 (2003-03-01), Freier
patent: 6600019 (2003-07-01), Prayaga et al.
patent: 6872541 (2005-03-01), Mills
patent: 7666432 (2010-02-01), Gomer et al.
patent: 2002/0058284 (2002-05-01), Winkel
patent: 2003/0003567 (2003-01-01), Barber et al.
patent: 2003/0022245 (2003-01-01), Mills
patent: 2004/0068095 (2004-04-01), Shimkets et al.
patent: 2005/0238620 (2005-10-01), Gomer et al.
patent: 28 49 570 (1980-06-01), None
patent: 1 090 630 (2001-04-01), None
patent: 54-5023 (1979-01-01), None
patent: 11-319542 (1999-11-01), None
patent: 9941285 (1999-08-01), None
patent: 99/45900 (1999-09-01), None
patent: 03097104 (2003-11-01), None
patent: 2004058292 (2003-12-01), None
patent: 2004059318 (2003-12-01), None
patent: 2004016750 (2004-02-01), None
patent: 2004059318 (2004-07-01), None
patent: 2005110474 (2005-11-01), None
patent: 2005115452 (2005-12-01), None
patent: 2006002438 (2006-01-01), None
patent: 03031572 (2008-10-01), None
Serum Amyloid P (SAP) Binds to a Wide Variety of Molecules and Structures; “Published Papers Detailing What SAP can Bind”; pp. 5.
Hind et al.; “Binding Specificity of Serum Amyloid P Component for the Pyruvate Acetal of Galactose”; J. Exp. Med., vol. 159; pp. 1058-1069, Apr. 1984.
Duckworth et al.; “The Structure of Agar Part I. Fractionation of a Complex Mixture of Polysaccharides”; Carbohydrate Research, vol. 16; pp. 189-197, 1971.
Young et al.; “The Structure of Agar Part III*. Pyruvic Acid, a Common Feature of Agars From Different Agarophytes”; Carbohydrate Research, vol. 16; pp. 446-448, 1971.
Schwalbe et al.; “Pentraxin Family of Proteins Interact Specifically with Phosphorylcholine and/or Phosporylethanolamine”; Biochemistry, vol. 31; pp. 4907-4615, 1992.
Weimann et al.; “Studies of Wound Healing: Effects of Calcium D-Panthothenate on the Migration, Proliferation and Protein Synthesis of Human Dermal Fibroblasts in Culture”; Internat. J. Vit. Nutr. Res., 69(2); pp. 113-119, 1999.
Gehring et al.; “Effect of Topically Applied Dexpanthenol on Epidermal Barrier Function and Stratum Corneum Hydration”; Arzneim.-Forsch./Drug Res.; 50(11); pp. 7, 2000.
Ishaque et al.; “Role of Vitamins in Determining Apoptosis and Extent of Suppression by bcl-2 During hybridoma Cell Culture”; Apoptosis; vol. 7, No. 3; pp. 231-239, 2002.
F.C. de Beer et al., “Fibronectin and C4-Binding Protein are Selectively Bound by Aggregated Amyloid Component”, The Rockefeller University Press, vol. 154, pp. 1134-1149, Oct. 1981.
Lawrence A. Potempa et al., “Effect of Divalent Metal Ions and pH Upon the Binding Reactivity of Human Serum Amyloid P Component, a C-Reactive Protein Homologue, for Zymosan”, The Journal of Biological Chemistry, vol. 260, pp. 12142-12147, Oct. 5, 1985.
Terry W. Du Clos, “C-Reactive Protein Reacts With the U1 Small Nuclear Ribonucleoprotein”, The Journal of Immunology, vol. 143, pp. 2553-2559, Oct. 15, 1989.
Marilyn R. Brown et al., “Receptor-Ligand Interactions Between Serum Amyloid P Component and Model Soluble Immune Complexes”, The Journal of Immunology, vol. 151, pp. 2087-2095, Aug. 15, 1993.
Lorraine L. Marnell et al., “C- Reactive Protein Binds to FcγR1 in Transfected COS Cells”, The American Association of Immunologists, 9 Pgs., Feb. 22, 1995.
Annalisa D'Andrea et al., “Stimulatory and Inhibitory Effects of Interleukin (IL)-4 and IL-13 on the Production of Cytokines by Human Peripheral Blood Mononuclear Cells: Priming for IL-12 and Tumor Necrosis Factor α Production”, The Rockefeller University Press, vol. 181, pp. 537-546, Feb. 1995.
Kamyar Zahedi, “Characterization of the Binding of Serum Amyloid P to Type IV Collagen”, The Journal of Biological Chemistry, vol. 271, No. 25, pp. 14897-14902, Jun. 21, 1996.
Marc Daëron, “Fc Receptor Biology”, www.arjournals.annualreviews.org , pp. 203-234, 1997.
Kamyar Zahedi, “Characterization of the Binding of Serum Amyloid P to Laminin”, The Journal of Biological Chemistry, vol. 272, No. 4, pp. 2143-2148, Jan. 24, 1997.
Carla J.C. de Haas et al., “A Synthetic Lipopolysaccharide-Binding Peptide Based on Amino Acids 27-39 of Serum Amyloid P Component Inhibits Lipopolysaccharide-Induced Responses in Human Blood”, The Journal of Immunology, pp. 3607-3615, 1998.
Dwaipayan Bharadwaj et al., “The Major Receptor for C-Reactive Protein on Leukocytes Is Fcγ Receptor II”, The Journal of Experimental Medicine, vol. 190 No. 4, pp. 585-590, Aug. 16, 1999.
M.C.M. Bickerstaff et al., “Serum Amyloid P Component Controls Chromatin Degration and Prevents Antinuclear Autoimmunity”, Nature Medicine, vol. 5, No. 6, pp. 694-697, Jun. 1999.
Fayyaz S. Sutterwala et al., “The Taming of IL-12 Suppressing the production of Proinflammatory Cytokines”, Journal of Leukocyte Biology, vol. 65, pp. 543-551, May 1999.
Richard F. Mortensen et al., “Regulation of Phagocytic Leukocyte Activities by C-reactive Protein”, Journal of Leukocyte Biology, vol. 67, pp. 495-500, Apr. 2000.
Mary-Pat Stein et al., “C-reactive Protein Binding to FcγRIIa on Human Monocytes and Neutrophils is Allele-Specific”, The Journal of Clinical Investigation, vol. 105, pp. 369-376, Feb. 2000.
Dwaipayan Bharadwaj et al., “Serum Amyloid P Component Binds to Fcγ Receptors and Opsonizes Particles for Phagocytosis”, The Journal of Immunology, vol. 166, pp. 6735-6741, 2001.
Eirikur Saeland et al., “Human C-reactive Protein Does not Bind to FcγRIIa on Phagocytic Cells”, The Journal of Clinical Investigation, vol. 107 No. 5, pp. 641-643, Mar. 2001.
Carolyn Mold et al., “Serum Amyloid P Component and C-Reactive Protein Mediate Phagocytosis Through Murine FcγRs”, The Journal of Immunology, vol. 166, pp. 1200-1205, 2001.
Katherine B. Bodman-Smith et al., “C-Reactive Protein-Mediated Phagocytosis and Phospholipase D Signalling Through the High-Affinity Receptor for Immunoglobulin G (FcγRI)”, The Journal of Immunology, vol. 107 No. 2, pp. 252-260, Oct. 2002.
Matthias Schmidt et al., “Identification of Circulating Fibrocytes as Precursors of Bronchial Myofibroblasts in Asthma”, The Journal of Immunology, vol. 170, pp. 380-389, Apr. 22, 2003.
Liju Yang et al., “Peripheral Blood Fibrocytes From Burn Patients: Identification and Quantification of Fibrocytes in Adherent Cells Cultured From Peripheral Blood Mononuclear Cells”, Laboratory Investigation, vol. 82, No. 9, pp. 1183-1192, Apr. 15, 2002.
Thomas A. Wynn, “IL-13 Effector Functions”, www.arjournals.annu
Gomer Richard
Pilling Darrell
Baker & Botts L.L.P.
Mertz Prema
William Marsh Rice University
LandOfFree
Treatment methods for fibrosis related disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment methods for fibrosis related disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment methods for fibrosis related disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4257274